This brand name is authorized in Estonia, France
The drug METAFLU contains one active pharmaceutical ingredient (API):
|
1
Sodium fluoride ¹⁸F
UNII 9L75099X6R - SODIUM FLUORIDE F-18
|
|
Sodium fluoride F18 is a radioactive diagnostic agent for positron emission tomography (PET) indicated for imaging of bone to define areas of altered osteogenic activity. Increased fluoride F18 ion deposition in bone can occur in areas of increased osteogenic activity during growth, infection, malignancy (primary or metastatic) following trauma, or inflammation of bone. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| V09IX06 | V Various → V09 Diagnostic radiopharmaceuticals → V09I Tumour detection → V09IX Other diagnostic radiopharmaceuticals for tumour detection | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EE | Ravimiamet | Identifier(s): 1777743, 1777754 |
| Country: FR | Base de données publique des médicaments | Identifier(s): 66488073 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
